South Korea Acne Vulgaris Market - Forecast(2020 - 2025)

Report Code: HCR 1370 Report Format: PDF + Excel (Delivery in 48 Hrs)

South Korea Acne Vulgaris Market Overview

South Korea Acne Vulgaris Market size is $119.56 in 2019, growing at a CAGR of 2.8% during the forecast period 2020-2025. Acne Vulgaris is a multifactorial skin disease that causes lesions on areas of the body with a large concentration of oil glands, such as face, chest, neck and back. It is a common disease of the pilosebaceous unit, involving abnormalities in sebum production, follicular epithelial desquamatin and bacterial proliferation. The disease occurs most frequently during childhood and adolescence also appear in adults. It occurs when dead skin cells, bacteria, and oil (sebum) block hair follicles. Acne vulgaris can cause psychological pressure, social withdrawal and reduced self-esteem in addition to carrying a significant risk of permanent facial scarring. There is also a rise in expenditure in the exploration of multiple alternatives to effectively treat Acne Vulgaris.

Report Coverage

The report: “South Korea Acne Vulgaris Market – Forecast (2020-2025)”, by IndustryARC covers an in-depth analysis of the following segments of the South Korea Acne Vulgaris Market. 

By Treatment: Systematic Therapy, Hormonal Therapy-Oral Contraceptives, Spironolactone, Cyproterone Acetate and Flutamide, Topical Antibiotics-Erythromycin, Clindamycin, Azithromycin and Nadifloxacin, Topical Retinoid-Adapalene, Tazaroteen, Tretinoin, Isothretinoin, Metretinide, Retinaldehyde and β-retinoyl glucuronide, Physical Treatment-Lesion removal-Comedones and Active deep inflammatory lesions, Phototherapy-Visible Light and Photodynamic Therapy, Benzyl Peroxides-Washes, Lotions, Cream and Gel, Other Treatments-Combination Therapy, Salicylic Acid, Gycolic Acid, Azelaic Acid and Others.

Key Takeaways

  • Increasing prevalence of skin-related issues and rising awareness regarding skin care products, accelerating the demand of South Korea Acne Vulgaris.
  • Changing lifestyle, upsurge in cosmetic expenditure and rising awareness of disease boosts the acne vulgaris treatment market growth within the region.
  • Growing demand for innovative therapeutics, and rising awareness among people of South Korea is set to accelerate market growth.

By Type - Segment Analysis

In 2019, Topical Retinoids South Korea Acne Vulgaris segment dominated the South Korea Acne Vulgaris Market in terms of revenue is estimated to grow at a CAGR of 3.2%. Skin sensitivity or irritation with use of topical retinoid is a minor challenge faced by this segment as people are apprehensive to its usage. Thus, many Korean skin care products tend to use very less or no retinol ingredients in their formulations. It is used to reduce acne as well as prevents aging, fine lines, dark spots and dull skin. Various studies conducted by Korean Society for Acne Research, have inferred that acne vulgaris is treated better by topical methods and also adapalene is used in combination with clindamycin or doxycycline for severe cases. According to International Trade Administration, South Korea is the 9th largest cosmetics market in the world. Thus, more skin care products are being produced here and their use is also high abetting towards the segmental growth of the market.

Drivers – South Korea Acne Vulgaris Market

  • Rise in Adoption of Skin Care Products

Growing conscious about the ingredients of skin care products and manufacturing process supports the market growth. For instance, according to a survey conducted by Philips, 44% of women in South Korea expect the use of more natural and organic ingredients rather than chemicals in skin care products. The market expansion is driven by increased demand for minimally invasive therapies combined with the fact that dermatologists tend to treat skin disorders with the use of topical applications or less invasive procedures such as lotion, creams or gels instead of surgical methods.

Challenges – South Korea Acne Vulgaris Market

  • Failure of Pivotal Clinical Trials

Failure of pivotal clinical trials for key candidates remains an impediment to the growth of South Korea Acne Vulgaris Market. Further, Off-label use of anti-acne drugs such as Diane-35 as birth-control measures lead to serious consequences such as breast cancer and venous thromboembolism (VTE) restraining the market growth. Key players in the market are also facing failures in the late-stage clinical trials that are another key factor obstructing the market growth. For instance, Olumacostat glasaretil (Dermira), SNA-001 (Sienna), XEN801 (Xenon), and JNJ-10229570 AAA (Valeant) have faced discontinuation in the recent past. 

South Korea Acne Vulgaris Industry Outlook 

Product Launches was the key strategy of the players in the South Korea Acne Vulgaris Industry. South Korea Acne Vulgaris top 10 companies include Bayer AG, Gladerma S.A., Pfizer Inc., Allergan, Bausch Health Company, GlaxoSmithKline Plc, Otsuka Pharmaceuticals, Jeilmedix Pharmaceutical, Kwan Dong Pharma, and Teva Pharmaceuticals.

Acquisitions/Product Launches

  • In February 2020, Bausch Health Company launched new telemedicine platform on Dermatology.com, to consult with a health care professional, order and potentially receive a prescription on-demand for many of the branded dermatology products particularly acne vulgaris and fine lines treatment products.
  • In November 2016, Pfizer and Allergan announced merger to create the world’s largest pharmaceutical powerhouse, which includes portfolio of brands from Botox, Kybella to Aczone for acne vulgaris.

1. South Korea Acne Vulgaris Market Overview
    1.1 Definitions and Scope
2. South Korea Acne Vulgaris Market - Executive Summary
    2.1 Market Revenue, Market Size and Key Trends 
    2.2 Key trends by Treatment
3. South Korea Acne Vulgaris Market Landscape
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis– Key Companies
    3.3 Market Share Analysis- Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. South Korea Acne Vulgaris Market - Forces
    4.1 Market Drivers
    4.2 Market Constraints/Challenges
    4.3 Porters Five Force Model
        4.3.1 Bargaining power of suppliers
        4.3.2 Bargaining powers of customers
        4.3.3 Threat of new entrants
        4.3.4 Rivalry among existing players
        4.3.5 Threat of substitutes 
5. South Korea Acne Vulgaris Market – Strategic Analysis
    5.1 Value Chain Analysis
    5.2 Opportunities Analysis
    5.3 Market Life Cycle
6. South Korea Acne Vulgaris Market – By Treatment (Market Size –$Million/$Billion)
    6.1 Systematic Therapy
    6.2 Hormonal Therapy
        6.2.1 Oral Contraceptives
        6.2.2 Spironolactone
        6.2.3 Cyproterone Acetate
        6.2.4 Flutamide
    6.3 Topical Antibiotics
        6.3.1 Erythromycin
        6.3.2 Clindamycin
        6.3.3 Azithromycin
        6.3.4 Nadifloxacin
    6.4 Topical Retinoid
        6.4.1 Adapalene
        6.4.2 Tazaroteen
        6.4.3 Tretinoin
        6.4.4 Isothretinoin
        6.4.5 Metretinide
        6.4.6 Retinaldehyde
        6.4.7 β-retinoyl glucuronide
    6.5 Physical Treatment
        6.5.1 Lesion removal
            6.5.1.1 Comedones
            6.5.1.2 Active deep inflammatory lesions
        6.5.2 Phototherapy
            6.5.2.1 Visible Light
            6.5.2.2 Photodynamic Therapy
    6.6 Benzyl Peroxides
        6.6.1 Washes
        6.6.2 Lotions
        6.6.3 Cream
        6.6.4 Gel
    6.7 Other Treatments
        6.7.1 Combination Therapy
        6.7.2 Salicylic Acid
        6.7.3 Gycolic Acid
        6.7.4 Azelaic Acid
        6.7.5 Others
7. South Korea Acne Vulgaris Market - Entropy
8. South Korea Acne Vulgaris Market Company Analysis
    8.1 Company 1
    8.2 Company 2
    8.3 Company 3
    8.4 Company 4
    8.5 Company 5
    8.6 Company 6
    8.7 Company 7
    8.8 Company 8
    8.9 Company 9
    8.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.